Amgen Inc. $AMGN is Aristotle Capital Management LLC’s 9th Largest Position

Aristotle Capital Management LLC lowered its position in Amgen Inc. (NASDAQ:AMGN) by 6.5% in the 1st quarter, according to its most recent 13F filing with the SEC. The firm owned 3,079,565 shares of the medical research company’s stock after selling 212,999 shares during the period. Amgen comprises approximately 2.3% of Aristotle Capital Management LLC’s holdings, making the stock its 9th largest position. Aristotle Capital Management LLC’s holdings in Amgen were worth $1,083,569,000 at the end of the most recent quarter.

A number of other institutional investors have also bought and sold shares of the business. Entropy Technologies LP bought a new stake in Amgen during the first quarter valued at about $3,223,000. Sustainable Insight Capital Management LLC lifted its holdings in shares of Amgen by 62.1% in the first quarter. Sustainable Insight Capital Management LLC now owns 1,357 shares of the medical research company’s stock worth $477,000 after buying an additional 520 shares in the last quarter. Bridgewater Advisors Inc. boosted its position in shares of Amgen by 2.3% during the first quarter. Bridgewater Advisors Inc. now owns 2,545 shares of the medical research company’s stock worth $852,000 after acquiring an additional 57 shares during the last quarter. Bollard Group LLC grew its stake in Amgen by 3.2% during the first quarter. Bollard Group LLC now owns 4,087 shares of the medical research company’s stock valued at $1,438,000 after acquiring an additional 126 shares in the last quarter. Finally, Hilltop Holdings Inc. grew its stake in Amgen by 77.2% during the first quarter. Hilltop Holdings Inc. now owns 6,089 shares of the medical research company’s stock valued at $2,142,000 after acquiring an additional 2,653 shares in the last quarter. Hedge funds and other institutional investors own 76.50% of the company’s stock.

Analysts Set New Price Targets

Several analysts have recently issued reports on the company. Erste Group Bank reaffirmed a “hold” rating on shares of Amgen in a report on Tuesday, May 5th. Wall Street Zen downgraded Amgen from a “buy” rating to a “hold” rating in a research report on Saturday, June 27th. Daiwa Securities Group decreased their target price on Amgen from $410.00 to $390.00 and set an “outperform” rating for the company in a research report on Wednesday, May 13th. Guggenheim upped their price target on shares of Amgen from $340.00 to $343.00 and gave the stock a “neutral” rating in a report on Monday, July 13th. Finally, Canaccord Genuity Group began coverage on shares of Amgen in a report on Monday, April 20th. They set a “hold” rating and a $366.00 price objective for the company. Two research analysts have rated the stock with a Strong Buy rating, eleven have assigned a Buy rating, fifteen have given a Hold rating and two have given a Sell rating to the company. Based on data from MarketBeat, the stock has an average rating of “Hold” and a consensus target price of $356.62.

Insider Buying and Selling

In other Amgen news, SVP Nancy A. Grygiel sold 1,237 shares of the stock in a transaction dated Monday, May 4th. The stock was sold at an average price of $323.73, for a total value of $400,454.01. Following the completion of the sale, the senior vice president directly owned 7,009 shares in the company, valued at approximately $2,269,023.57. This trade represents a 15.00% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Company insiders own 0.85% of the company’s stock.

Amgen Stock Up 1.2%

NASDAQ:AMGN opened at $376.04 on Friday. The company’s 50-day simple moving average is $351.28 and its 200-day simple moving average is $351.80. The company has a debt-to-equity ratio of 5.65, a quick ratio of 1.01 and a current ratio of 1.26. Amgen Inc. has a fifty-two week low of $269.77 and a fifty-two week high of $391.29. The stock has a market capitalization of $202.95 billion, a P/E ratio of 26.17, a P/E/G ratio of 3.76 and a beta of 0.41.

Amgen (NASDAQ:AMGN) last posted its quarterly earnings data on Thursday, April 30th. The medical research company reported $5.15 EPS for the quarter, topping the consensus estimate of $4.77 by $0.38. Amgen had a net margin of 20.96% and a return on equity of 137.41%. The firm had revenue of $8.62 billion during the quarter, compared to analyst estimates of $8.58 billion. During the same quarter in the previous year, the business posted $4.90 EPS. Amgen’s revenue was up 5.8% on a year-over-year basis. Amgen has set its FY 2026 guidance at 21.700-23.100 EPS. On average, equities analysts anticipate that Amgen Inc. will post 22.31 earnings per share for the current fiscal year.

About Amgen

Amgen Inc (NASDAQ: AMGN) is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen’s work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen’s commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.